ArticlePharmacoEconomics - open2025

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.

Tanawan Kongmalai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.